Karageorgas Theophanis P, Tseronis Dimitrios D, Mavragani Clio P
Department of Rheumatology, General Hospital of Athens G.Gennimatas, Mesogion St 154, 11527 Athens, Greece.
J Biomed Biotechnol. 2011;2011:273907. doi: 10.1155/2011/273907. Epub 2011 Nov 16.
Growing evidence over the last few years suggests a central role of type I IFN pathway in the pathogenesis of systemic autoimmune disorders. Data from clinical and genetic studies in patients with systemic lupus erythematosus (SLE) and lupus-prone mouse models, indicates that the type I interferon system may play a pivotal role in the pathogenesis of several lupus and associated clinical features, such as nephritis, neuropsychiatric and cutaneous lupus, premature atherosclerosis as well as lupus-specific autoantibodies particularly against ribonucleoproteins. In the current paper, our aim is to summarize the latest findings supporting the association of type I IFN pathway with specific clinical manifestations in the setting of SLE providing insights on the potential use of type I IFN as a therapeutic target.
过去几年越来越多的证据表明，I型干扰素通路在系统性自身免疫性疾病的发病机制中起核心作用。来自系统性红斑狼疮（SLE）患者的临床和遗传学研究以及狼疮易感小鼠模型的数据表明，I型干扰素系统可能在几种狼疮及其相关临床特征（如肾炎、神经精神性和皮肤性狼疮、过早动脉粥样硬化以及特别是针对核糖核蛋白的狼疮特异性自身抗体） 的发病机制中起关键作用。在本文中，我们的目的是总结支持I型干扰素通路与SLE背景下特定临床表现之间关联的最新发现，为将I型干扰素作为治疗靶点的潜在用途提供见解。
